OrthoPediatrics (NASDAQ:KIDS) Given New $40.00 Price Target at BTIG Research

OrthoPediatrics (NASDAQ:KIDS – Get Free Report) had its price objective increased by analysts at BTIG Research from $30.00 to $40.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. BTIG Research‘s price objective would suggest a potential upside of 27.35% from the stock’s previous close.

KIDS has been the subject of several other reports. Truist Financial raised their price target on shares of OrthoPediatrics from $22.00 to $28.00 and gave the company a “hold” rating in a report on Wednesday, October 28th. Lake Street Capital boosted their price target on shares of OrthoPediatrics from $34.00 to $38.00 and gave the company a “buy” rating in a research report on Wednesday, October 28th. TD Cowen upped their price target on shares of OrthoPediatrics from $23.00 to $28.00 and gave the stock a “buy” rating in a report on Wednesday, October 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of OrthoPediatrics in a research report on Tuesday, November 3rd. Finally, Piper Sandler reiterated an “overweight” rating and issued a $30.00 price objective (up from $25.00) on shares of OrthoPediatrics in a research report on Wednesday, October 28th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $32.00.

Get Our Latest Stock Report on OrthoPediatrics

OrthoPediatrics Price Performance

KIDS stock opened at $31.41 on Wednesday. The firm has a 50 day moving average of $25.44 and a 200-day moving average of $20.44. The company has a current ratio of 4.55, a quick ratio of 2.00 and a debt-to-equity ratio of 0.29. OrthoPediatrics has a 12 month low of $14.42 and a 12 month high of $34.53. The firm has a market capitalization of $820.12 million, a P/E ratio of -21.96 and a beta of 0.90.

OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last issued its quarterly earnings data on Tuesday, October 27th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.02). The firm had revenue of $72.66 million for the quarter, compared to analysts’ expectations of $68.50 million. OrthoPediatrics had a negative net margin of 12.83% and a negative return on equity of 8.10%. As a group, sell-side analysts predict that OrthoPediatrics will post -1.09 earnings per share for the current fiscal year.

Insider Buying and Selling at OrthoPediatrics

In other news, Director David R. Pelizzon sold 302,369 shares of the company’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $21.01, for a total value of $6,352,772.69. Following the completion of the transaction, the director directly owned 6,201,764 shares in the company, valued at approximately $130,299,061.64. This represents a 4.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Jennifer N. Pritzker sold 302,369 shares of the company’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $21.01, for a total value of $6,352,772.69. Following the completion of the transaction, the insider owned 6,201,764 shares of the company’s stock, valued at $130,299,061.64. The trade was a 4.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 2,100,000 shares of company stock worth $46,747,931 over the last 90 days. Corporate insiders own 32.50% of the company’s stock.

Institutional Trading of OrthoPediatrics

Hedge funds have recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in OrthoPediatrics in the second quarter worth approximately $24,347,000. AIGH Capital Management LLC grew its position in OrthoPediatrics by 334.4% during the third quarter. AIGH Capital Management LLC now owns 1,171,765 shares of the company’s stock valued at $26,095,000 after acquiring an additional 902,000 shares during the last quarter. Nantahala Capital Management LLC bought a new position in OrthoPediatrics during the second quarter valued at approximately $4,636,002. AWM Investment Company Inc. purchased a new position in shares of OrthoPediatrics during the second quarter worth approximately $4,537,000. Finally, Granahan Investment Management LLC raised its stake in shares of OrthoPediatrics by 35.1% during the first quarter. Granahan Investment Management LLC now owns 896,741 shares of the company’s stock worth $14,231,000 after acquiring an additional 232,760 shares in the last quarter. Institutional investors own 69.05% of the company’s stock.

OrthoPediatrics Company Profile

(Get Free Report)

OrthoPediatrics Corp. develops and markets orthopedic implants and instruments designed specifically for children and adolescents. Its products support surgeons treating a range of pediatric conditions, including fractures, spinal deformities, limb-length differences and other orthopedic disorders. The company’s portfolio includes systems for trauma and deformity correction, scoliosis treatment, limb lengthening and external fixation, as well as specialized surgical instruments. It also provides related education and support for pediatric orthopedic surgeons and care teams.

Read More

Analyst Recommendations for OrthoPediatrics (NASDAQ:KIDS)

Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.